Effect of major CYP2C19 genetic polymorphisms on <em>Helicobacter pylori</em> eradication based on different treatment regimens

Zihlif,Malek; Bashaireh,Banan; Rashid,Mohammed; Almadani,Zaid; Jarrar,Yazun

doi:10.3892/br.2021.1485

Effect of major CYP2C19 genetic polymorphisms on Helicobacter pylori eradication based on different treatment regimens

Authors:
- Malek Zihlif
- Banan Bashaireh
- Mohammed Rashid
- Zaid Almadani
- Yazun Jarrar
View Affiliations

Affiliations: Department of Pharmacology, Faculty of Medicine, The University of Jordan, Amman 11492, Jordan, Department of Internal Medicine, Faculty of Medicine, The University of Jordan, Amman 11492, Jordan, Department of Pharmacy, Al‑Zaytoonah University of Jordan, Amman 11731, Jordan
Published online on: November 8, 2021 https://doi.org/10.3892/br.2021.1485
Article Number: 2

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Helicobacter pylori (H. pylori) infection is a global issue. Its eradication in affected individuals is important to prevent several further complications that may occur if left untreated. Proton pump inhibitors (PPIs) serve an important role in the eradication regimens of H. pylori. PPIs are metabolized primarily through the CYP2C19 enzyme in the liver. Inter‑individual variation in the response to eradication treatment may partly be due to variations in the metabolism of PPIs. The aim of this study was to determine whether there was any association between CYP2C19 genetic polymorphisms and the response to eradication therapy amongst Jordanians infected with H. pylori receiving lansoprazole‑based regimens. The present study was approved by the Institutional Review Board of The University of Jordan Hospital. A total of 141 patients infected with H. pylori were genotyped for the polymorphisms CYP2C19^*2 and CYP2C19^*17 using the PCR‑restriction fragment length polymorphism assay method. Patients received lansoprazole‑based triple or sequential therapy. The assessment of eradication was performed using either a H. pylori stool antigen test or from feedback from patients regarding their improvement. Eradication rates were 84.6% and 64.5% in the intermediate‑metabolizer and extensive‑metabolizer group, respectively. This difference was not statistically significant. Moreover, no significant association was found between the carriers of the CYP2C19^*17 polymorphism and the response to eradication therapy. These findings suggest that there was no significant association between the CYP2C19 genotype and the response to eradication therapy amongst Jordanians infected with H. pylori.

View Figures

View References

1	Malaty HM and Nyren O: Epidemiology of Helicobacter pylori infection. Helicobacter. 8 (Suppl 1):8–12. 2003.PubMed/NCBI View Article : Google Scholar
2	Chey WD and Wong BC: Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol. 102:1808–1825. 2007.PubMed/NCBI View Article : Google Scholar
3	Shin JM and Sachs G: Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 10:528–534. 2008.PubMed/NCBI View Article : Google Scholar
4	Lee SJ: Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine. Front Genet. 3(318)2013.PubMed/NCBI View Article : Google Scholar
5	Ishizaki T and Horai Y: Review article: Cytochrome P450 and the metabolism of proton pump inhibitors--emphasis on rabeprazole. Aliment Pharmacol Ther. 13 (Suppl 3):27–36. 1999.PubMed/NCBI View Article : Google Scholar
6	Zalloum I, Hakooz N and Arafat T: Genetic polymorphism of CYP2C19 in a Jordanian population: Influence of allele frequencies of CYP2C19^1 and CYP2C19^2 on the pharmacokinetic profile of lansoprazole. Mol Biol Rep. 39:4195–4200. 2012.PubMed/NCBI View Article : Google Scholar
7	Li-Wan-Po A, Girard T, Farndon P, Cooley C and Lithgow J: Pharmacogenetics of CYP2C19: Functional and clinical implications of a new variant CYP2C19^*17. Br J Clin Pharmacol. 69:222–230. 2010.PubMed/NCBI View Article : Google Scholar
8	Sim SC, Risinger C, Dahl ML, Aklillu E, Christensen M, Bertilsson L and Ingelman-Sundberg M: A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 79:103–113. 2006.PubMed/NCBI View Article : Google Scholar
9	Charan J and Biswas T: How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 35:121–126. 2013.PubMed/NCBI View Article : Google Scholar
10	Sugimoto K, Uno T, Yamazaki H and Tateishi T: Limited frequency of the CYP2C19^*17 allele and its minor role in a Japanese population. Br J Clin Pharmacol. 65:437–439. 2008.PubMed/NCBI View Article : Google Scholar
11	Dowdle WR: The principles of disease elimination and eradication. Bull World Health Organ. 76 (Suppl 2):22–25. 1998.PubMed/NCBI
12	Yang JC, Lu CW and Lin CJ: Treatment of Helicobacter pylori infection: Current status and future concepts. World J Gastroenterol. 20:5283–5293. 2014.PubMed/NCBI View Article : Google Scholar
13	Mégraud F and Lamouliatte H: Review article: The treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 17:1333–1343. 2003.PubMed/NCBI View Article : Google Scholar
14	Jarrar Y and Lee SJ: The functionality of UDP-Glucuronosyltransferase genetic variants and their association with drug responses and human diseases. J Pers Med. 11(11)2021.PubMed/NCBI View Article : Google Scholar
15	Kuo CH, Lu CY, Shih HY, Liu CJ, Wu MC, Hu HM, Hsu WH, Yu FJ, Wu DC and Kuo FC: CYP2C19 polymorphism influences Helicobacter pylori eradication. World J Gastroenterol. 20:16029–16036. 2014.PubMed/NCBI View Article : Google Scholar
16	Zhao F, Wang J, Yang Y, Wang X, Shi R, Xu Z, Huang Z and Zhang G: Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: A meta-analysis. Helicobacter. 13:532–541. 2008.PubMed/NCBI View Article : Google Scholar
17	Shirasaka Y, Chaudhry AS, McDonald M, Prasad B, Wong T, Calamia JC, Fohner A, Thornton TA, Isoherranen N, Unadkat JD, et al: Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content. Pharmacogenomics J. 16:375–387. 2016.PubMed/NCBI View Article : Google Scholar
18	Miki I, Aoyama N, Sakai T, Shirasaka D, Wambura CM, Maekawa S, Kuroda K, Tamura T, Kita T, Sakaeda T, et al: Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol. 15:27–33. 2003.PubMed/NCBI View Article : Google Scholar
19	Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Inaba T, Yamamoto K, Okada H, Yokota K, Oguma K, et al: Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2019 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Am J Gastroenterol. 98:2403–2408. 2003.PubMed/NCBI View Article : Google Scholar
20	Kawabata H, Habu Y, Tomioka H, Kutsumi H, Kobayashi M, Oyasu K, Hayakumo T, Mizuno S, Kiyota K, Nakajima M, et al: Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther. 17:259–264. 2003.PubMed/NCBI View Article : Google Scholar
21	Okudaira K, Furuta T, Shirai N, Sugimoto M and Miura S: Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. Aliment Pharmacol Ther. 21:491–497. 2005.PubMed/NCBI View Article : Google Scholar
22	Kurzawski M, Gawrońska-Szklarz B, Wrześniewska J, Siuda A, Starzyńska T and Droździk M: Effect of CYP2C19^17 gene variant on Helicobacter pylori* eradication in peptic ulcer patients. Eur J Clin Pharmacol. 62:877–880. 2006.PubMed/NCBI View Article : Google Scholar
23	Gawrońska-Szklarz B, Siuda A, Kurzawski M, Bielicki D, Marlicz W and Droździk M: Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. Eur J Clin Pharmacol. 66:681–687. 2010.PubMed/NCBI View Article : Google Scholar
24	Park HG, Jung MK, Jung JT, Kwon JG, Kim EY, Seo HE, Lee JH, Yang CH, Kim ES, Cho KB, et al: Randomised clinical trial: A comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients. Aliment Pharmacol Ther. 35:56–65. 2012.PubMed/NCBI View Article : Google Scholar
25	Choi HS, Chun HJ, Park SH, Keum B, Seo YS, Kim YS, Jeen YT, Um SH, Lee HS, Kim CD, et al: Comparison of sequential and 7-, 10-, 14-d triple therapy for Helicobacter pylori infection. World J Gastroenterol. 18:2377–2382. 2012.PubMed/NCBI View Article : Google Scholar
26	Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, et al: Taiwan Helicobacter Consortium: Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: A multicentre, open-label, randomised trial. Lancet. 381:205–213. 2013.PubMed/NCBI View Article : Google Scholar
27	Gaikovitch EA, Cascorbi I, Mrozikiewicz PM, Brockmöller J, Frötschl R, Köpke K, Gerloff T, Chernov JN and Roots I: Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clin Pharmacol. 59:303–312. 2003.PubMed/NCBI View Article : Google Scholar
28	Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E and Ingelman-Sundberg M: Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br J Clin Pharmacol. 52:447–450. 2001.PubMed/NCBI View Article : Google Scholar
29	Rudberg I, Mohebi B, Hermann M, Refsum H and Molden E: Impact of the ultrarapid CYP2C19^*17 allele on serum concentration of escitalopram in psychiatric patients. Clin Pharmacol Ther. 83:322–327. 2008.PubMed/NCBI View Article : Google Scholar
30	Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS and Mizugaki M: Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol. 53:596–603. 2002.PubMed/NCBI View Article : Google Scholar
31	Pedersen RS, Brasch-Andersen C, Sim SC, Bergmann TK, Halling J, Petersen MS, Weihe P, Edvardsen H, Kristensen VN, Brøsen K, et al: Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: Identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol. 66:1199–1205. 2010.PubMed/NCBI View Article : Google Scholar
32	Bravo-Villalta HV, Yamamoto K, Nakamura K, Bayá A, Okada Y and Horiuchi R: Genetic polymorphism of CYP2C9 and CYP2C19 in a Bolivian population: An investigative and comparative study. Eur J Clin Pharmacol. 61:179–184. 2005.PubMed/NCBI View Article : Google Scholar
33	Chen L, Qin S, Xie J, Tang J, Yang L, Shen W, Zhao X, Du J, He G, Feng G, et al: Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China. Pharmacogenomics. 9:691–702. 2008.PubMed/NCBI View Article : Google Scholar
34	Lee SJ, Kim WY, Kim H, Shon JH, Lee SS and Shin JG: Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Drug Metab Dispos. 37:2262–2269. 2009.PubMed/NCBI View Article : Google Scholar